CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00292-07v1
15/1/172    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleury, M. J. J.
Right arrow Articles by Coursaget, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleury, M. J. J.
Right arrow Articles by Coursaget, P.

 Previous Article

Clinical and Vaccine Immunology, January 2008, p. 172-175, Vol. 15, No. 1
1071-412X/08/$08.00+0     doi:10.1128/CVI.00292-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing Pseudovirions{triangledown}

Maxime J. J. Fleury,1,2,3 Antoine Touzé,1,2,3 Silvia de Sanjosé,4 F. Xavier Bosch,4 Joellen Klaustermeiyer,4 and Pierre Coursaget1,2,3*

INSERM U618, Tours, France,1 University François Rabelais, Tours, France,2 IFR 136, Agents Transmissibles et Infectiologie, Faculté des Sciences Pharmaceutiques, Tours, France,3 Servei d'Epidemiologia i Registre del Cancer, Institut Catala d'Oncologia, Barcelona, Spain4

Received 4 July 2007/ Returned for modification 28 August 2007/ Accepted 29 October 2007

The aim of this study was to develop a highly sensitive human papillomavirus type 31 (HPV31) neutralization assay based on the production of pseudovirions carrying luciferase. Neutralizing antibodies against HPV31 were investigated in a set of HPV31 monoclonal antibodies and in women with evidence of HPV31 infection. Neutralizing antibodies were detected in 78% of subjects with a positive enzyme-linked immunosorbent assay.

* Corresponding author. Mailing address: Laboratoire Vecteurs, Virus & Vaccins, INSERM U618, Faculté des Sciences Pharmaceutiques, 31 Ave. Monge, 37200 Tours, France. Phone: 33 2 47 36 72 56. Fax: 33 2 47 36 71 88. E-mail: coursaget{at}univ-tours.fr

{triangledown} Published ahead of print on 7 November 2007.

Clinical and Vaccine Immunology, January 2008, p. 172-175, Vol. 15, No. 1
1071-412X/08/$08.00+0     doi:10.1128/CVI.00292-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.